Paul K Wotton has sold VCEL and made no open-market buys since Jun 2018

Dr. Paul K. Wotton is a biopharmaceutical executive and corporate insider who serves as a director of Vericel Corporation (NASDAQ: VCEL), where he has been a member of the Board of Directors since 2015 and sits on the Governance & Nominating and Compensation Committees.( As an insider, he has recently traded Vericel stock in his capacity as a board director.( Wotton is also Executive Director and Chairman of the Board of the Rice Biotech Launch Pad (RBL LLC) and an Adjunct Professor at Rice University, reflecting his role in biotech venture creation and academic collaboration.(

Over a thirty-year career in biotech and pharma, Wotton has held multiple CEO roles, including President and CEO of Ocata Therapeutics until its acquisition by Astellas Pharma in 2016, President and CEO of Antares Pharma, Founding President and CEO of Sigilon Therapeutics, and CEO of Obsidian Therapeutics and Topigen Pharmaceuticals.( He has also served on the boards of Cynata Therapeutics (as Chairman), Kytopen (Chair), Veloxis Pharmaceuticals, Combined Therapeutics, and as co‑founder and director of Avenge Bio.( A named inventor on numerous patents, Wotton was recognized as an Ernst & Young Entrepreneur of the Year (Regional, NJ, Life Sciences) in 2014 and listed among World Biz Magazine’s “Top 100 Innovation CEOs.”( He holds a B.Pharm from University College London and a Ph.D. in Pharmaceutical Sciences from the University of Nottingham.(

Written by Perplexity from public sources.